{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:03:55Z","timestamp":1789617835520,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jtha.2023.09.017","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T21:37:29Z","timestamp":1695937049000},"page":"112-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Thrombin generation on vascular cells in the presence of factor VIII and\/or emicizumab"],"prefix":"10.1016","volume":"22","author":[{"given":"S\u00e9nad\u00e9","family":"Atsou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lia","family":"Schellenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Lagrange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lacolley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Lenting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile V.","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier D.","family":"Christophe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Regnault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.09.017_bib1","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","article-title":"Haemophilias A and B","volume":"361","author":"Bolton-Maggs","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2023.09.017_bib2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.09.017_bib3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1208024","article-title":"Factor VIII products and inhibitor development in severe hemophilia A","volume":"368","author":"Gouw","year":"2013","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jtha.2023.09.017_bib4","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A\u00a0randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.09.017_bib5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/hae.12602","article-title":"Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors","volume":"21","author":"Ewing","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.09.017_bib6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.5045\/br.2015.50.3.173","article-title":"The efficacy of bypassing agents in surgery of hemophilia patients with inhibitors","volume":"50","author":"Ju","year":"2015","journal-title":"Blood Res"},{"key":"10.1016\/j.jtha.2023.09.017_bib7","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2023.09.017_bib8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12185-018-2548-6","article-title":"Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia","volume":"111","author":"Chowdary","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2023.09.017_bib9","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/MOH.0000000000000364","article-title":"Targeting activated protein C to treat hemophilia","volume":"24","author":"Polderdijk","year":"2017","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jtha.2023.09.017_bib10","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A\u00a0bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2023.09.017_bib11","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood.2020010331","article-title":"A\u00a0factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice","volume":"138","author":"\u00d8stergaard","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.09.017_bib12","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in Hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.09.017_bib13","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.09.017_bib14","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2023.09.017_bib15","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A\u00a0multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.09.017_bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/hae.13618","article-title":"The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study","volume":"25","author":"Oldenburg","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.09.017_bib17","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/bloodadvances.2019000849","article-title":"Laboratory monitoring of hemophilia A treatments: new challenges","volume":"4","author":"Lenting","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.09.017_bib18","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/jth.13215","article-title":"A\u00a0critical appraisal of one-stage and chromogenic assays of factor VIII activity","volume":"14","author":"Peyvandi","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.09.017_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12561","article-title":"The effect of emicizumab and bypassing agents in patients with hemophilia - an in\u00a0vitro study","volume":"5","author":"Schultz","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.09.017_bib20","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1111\/jth.14887","article-title":"Non-additive effect on thrombin generation when a plasma-derived factor VIII\/von Willebrand factor (FVIII\/VWF) is combined with emicizumab in\u00a0vitro","volume":"18","author":"Bravo","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.09.017_bib21","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.3324\/haematol.2017.185330","article-title":"Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab","volume":"103","author":"Dargaud","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2023.09.017_bib22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/hae.14213","article-title":"Comparison of bypassing agents in patients on emicizumab using global hemostasis assays","volume":"27","author":"Kizilocak","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2023.09.017_bib23","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/cvr\/cvs274","article-title":"Cyclic stretch-induced thrombin generation by rat vascular smooth muscle cells is mediated by the integrin alphavbeta3 pathway","volume":"96","author":"Mao","year":"2012","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jtha.2023.09.017_bib24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000073575","article-title":"The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability","volume":"32","author":"Hemker","year":"2002","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.jtha.2023.09.017_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/jth.14203","article-title":"In\u00a0vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents","author":"Hartmann","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.09.017_bib26","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.thromres.2012.02.021","article-title":"Tissue factor encryption and decryption: facts and controversies","volume":"129","author":"Rao","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2023.09.017_bib27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1083\/jcb.101.2.363","article-title":"Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta","volume":"101","author":"Maruyama","year":"1985","journal-title":"J\u00a0Cell Biol"},{"key":"10.1016\/j.jtha.2023.09.017_bib28","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1016\/S0021-9258(18)42786-X","article-title":"Thrombomodulin is preferentially expressed in Balb\/c lung microvessels","volume":"267","author":"Ford","year":"1992","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2023.09.017_bib29","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1042\/bj2230599","article-title":"Binding of human blood-coagulation Factors IXa and X to phospholipid membranes","volume":"223","author":"Mertens","year":"1984","journal-title":"Biochem J"},{"key":"10.1016\/j.jtha.2023.09.017_bib30","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1742-4658.2005.05070.x","article-title":"Factor VIIIa regulates substrate delivery to the intrinsic factor X-activating complex","volume":"273","author":"Panteleev","year":"2006","journal-title":"FEBS J"},{"key":"10.1016\/j.jtha.2023.09.017_bib31","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1177\/1747493017709671","article-title":"Analyses of thrombi in acute ischemic stroke: a consensus statement on current knowledge and future directions","volume":"12","author":"De Meyer","year":"2017","journal-title":"Int J Stroke"},{"key":"10.1016\/j.jtha.2023.09.017_bib32","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1538-7933.2003.00617.x","article-title":"Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system","volume":"2","author":"Allen","year":"2004","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.09.017_bib33","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"Kitazawa","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.09.017_bib34","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1111\/jth.14957","article-title":"Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: new case with detailed laboratory evaluation","volume":"18","author":"Harkins Druzgal","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.09.017_bib35","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1172\/JCI111377","article-title":"Regulation of factor IXa in\u00a0vitro in human and mouse plasma and in\u00a0vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors","volume":"73","author":"Fuchs","year":"1984","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2023.09.017_bib36","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1182\/blood.V96.10.3459","article-title":"Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein","volume":"96","author":"Neels","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.09.017_bib37","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1182\/blood.V79.8.2039.2039","article-title":"Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in\u00a0vivo","volume":"79","author":"Bauer","year":"1992","journal-title":"Blood"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623007195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623007195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:40:45Z","timestamp":1761536445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623007195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1538783623007195"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.09.017","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombin generation on vascular cells in the presence of factor VIII and\/or emicizumab","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}